- Exchange: Tel Aviv
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Pluristem Therapeutics Inc
+ Add to WatchlistPSTI:IT
1,109.00 ILs 14.00 1.28%As of 09:24:02 ET on 05/19/2013.
Snapshot for Pluristem Therapeutics Inc (PSTI)
| Open: | 1,104.00 | Day's Range: | 1,100.00 - 1,117.00 | Volume: | 114,279 |
|---|---|---|---|---|---|
| Previous Close: | 1,109.00 | 52wk Range: | 902.00 - 1,987.00 | 1-Yr Rtn: | +13.34% |
Key Statistics for PSTI
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(06/2013) | - |
| Relative P/E vs. TA-100 | - |
| Earnings Per Share (USD) (ttm) | -0.3500 |
| Est. EPS (USD) (06/2013) | -0.3600 |
| Est. PEG Ratio | - |
| Market Cap (M ILS) | 650.30 |
| Shares Outstanding (M) | 58.64 |
| 30 Day Average Volume | 124,708 |
| Price/Book (mrq) | 2.7763 |
| Price/Sale (ttm) | 232.6791 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 09/10/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PSTI
Company Profile & Key Executives for PSTI
Pluristem Therapeutics, Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The Company focuses on cell therapy to treat severe blood, cardiovascular, autoimmune, and other disorders.
| Zami AbermanChairman/President/CEO | Yaky YanayExec VP/CFO/Secretary |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PSTI News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page